Brokers Offer Predictions for AMLX Q1 Earnings

Key Points

• HC Wainwright expects Amylyx to post a Q1 2027 loss of $0.38 per share, with projected losses narrowing to $0.32 per share by Q4. Its rating is Buy with a $55 price target.
• Analyst sentiment is generally positive but mixed: MarketBeat reports a Moderate Buy consensus and an average price target of $44.14, alongside one Sell rating.
• Amylyx’s latest reported quarterly loss of $0.38 per share matched consensus. Shares opened at $27.62, and institutional investors own 95.84% of the stock.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Amylyx Pharmaceuticals in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.38) per share for the quarter. HC Wainwright has a "Buy" rating and a $55.00 price target on the stock. The consensus estimate for Amylyx Pharmaceuticals' current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals' Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.35) EPS and Q4 2027 earnings at ($0.32) EPS.

Other research analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research report on Tuesday. Mizuho upped their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an "outperform" rating in a research note on Tuesday, August 18th. Robert W. Baird increased their target price on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 19th. Wolfe Research raised shares of Amylyx Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 17th. Finally, Stifel Nicolaus set a $45.00 price target on shares of Amylyx Pharmaceuticals in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $44.14.

Amylyx Pharmaceuticals Price Performance

NASDAQ AMLX opened at $27.62 on Friday. The company has a 50 day simple moving average of $30.15 and a 200-day simple moving average of $20.35. The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of -19.31 and a beta of -0.09. Amylyx Pharmaceuticals has a 52-week low of $10.83 and a 52-week high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38).

Insider Transactions at Amylyx Pharmaceuticals

In related news, Director George M. Milne, Jr. sold 30,000 shares of the business's stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $27.70, for a total value of $831,000.00. Following the completion of the sale, the director owned 782,881 shares of the company's stock, valued at approximately $21,685,803.70. The trade was a 3.69% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Camille L. Bedrosian sold 10,028 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $32.40, for a total value of $324,907.20. Following the completion of the transaction, the insider owned 278,064 shares in the company, valued at $9,009,273.60. This represents a 3.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 60,374 shares of company stock valued at $1,815,257 over the last 90 days. Company insiders own 10.90% of the company's stock.

Institutional Trading of Amylyx Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in Amylyx Pharmaceuticals in the 2nd quarter worth approximately $158,534,000. Jupiter Topco LLC bought a new stake in Amylyx Pharmaceuticals during the second quarter worth approximately $94,014,000. Janus Henderson Group PLC grew its holdings in Amylyx Pharmaceuticals by 11.6% during the first quarter. Janus Henderson Group PLC now owns 4,986,073 shares of the company's stock valued at $69,257,000 after purchasing an additional 520,201 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in Amylyx Pharmaceuticals during the second quarter valued at approximately $18,912,000. Finally, Almitas Capital LLC bought a new position in shares of Amylyx Pharmaceuticals in the second quarter valued at approximately $17,509,000. 95.84% of the stock is owned by institutional investors.

About Amylyx Pharmaceuticals

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.